Search
Showing results for "1"
It may only have been a matter of months since Abby Carlon was diagnosed with type 1 diabetes but already the 10-year-old knows more than most about the condition. That’s because she’s always kept an eye out for her little sister Mia who was diagnosed with type 1 diabetes when she was three.
Looking at him now, it’s hard to believe busy one-year-old toddler Kye Gilbert was extremely unwell in Perth Children’s Hospital’s critical care unit with a new diagnosis of type 1 diabetes just a few months ago.
Adolescents and young adults with Type 1 Diabetes are invited to be co-researchers at a summit to help develop the Children’s Diabetes Centre’s new exercise gui
The Rio Tinto Children's Diabetes Centre; a Breakthrough T1D Centre of Excellence is excited the announce the latest round of seed funding recipients.
Advanced hybrid closed-loop (AHCL) therapy improves glycemia. However, it is not known if there is an improvement in overall outcomes with AHCL for youth with type 1 diabetes (T1D) at high risk of diabetes-related complications. The study aimed to capture the experiences of youth with suboptimal glycemic control when commencing AHCL therapy in a clinical trial setting.
To investigate how dieting is portrayed on TikTok and the potential implications for public health considering the effect of diet culture on eating disorders amongst young people.
One of the 50 most influential scientists in the world today, Professor Leroy Hood, delivered The Kids Research Institute Australia Community Lecture on Tue December 1st.
Find out about upcoming school holiday workshops at Scitech.
This study examined the safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric population.
Aboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules.